lomudal 20 mg/ml silmätipat, liuos
opella healthcare france sas - sodium cromoglicate - silmätipat, liuos - 20 mg/ml - natriumkromoglikaatti
lecrolyn 20 mg/ml silmätipat, liuos
santen oy - sodium cromoglicate - silmätipat, liuos - 20 mg/ml - natriumkromoglikaatti
lecrolyn 20 mg/ml silmätipat, liuos, kerta-annospakkaus
santen oy - sodium cromoglicate - silmätipat, liuos, kerta-annospakkaus - 20 mg/ml - natriumkromoglikaatti
lomudal 40 mg/ml silmätipat, liuos, kerta-annospakkaus
opella healthcare france sas - sodium cromoglicate - silmätipat, liuos, kerta-annospakkaus - 40 mg/ml - natriumkromoglikaatti
lecrolyn 40 mg/ml silmätipat, liuos
santen oy - sodium cromoglicate - silmätipat, liuos - 40 mg/ml - natriumkromoglikaatti
lecrolyn 40 mg/ml silmätipat, liuos, kerta-annospakkaus
santen oy - sodium cromoglicate - silmätipat, liuos, kerta-annospakkaus - 40 mg/ml - natriumkromoglikaatti
lecrolyn sine 40 mg/ml silmätipat, liuos
santen oy - sodium cromoglicate - silmätipat, liuos - 40 mg/ml - natriumkromoglikaatti
zavicefta
pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - systeemiset bakteerilääkkeet, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.
lomudal nasal 5.2 mg/annos nenäsumute, liuos
sanofi oy - natrii cromoglicas - nenäsumute, liuos - 5.2 mg/annos - natriumkromoglikaatti
glinor 5.2 mg/annos nenäsumute, liuos
ratiopharm gmbh - natrii cromoglicas - nenäsumute, liuos - 5.2 mg/annos - natriumkromoglikaatti